Tag: Blood Brain Barrier

08Sep 2016 by Ronny Allan 18 Comments

Serotonin – the NET effect

Serotonin – the NET effect

Awareness, Diet and Nutrition, Living with Neuroendocrine Cancer, Technical NETs

[caption id="attachment_16272" align="aligncenter" width="640"] Credit background picture: A team of researchers from Case Western Reserve University School of Medicine have used high-powered microscopes for the first time to view serotonin activating its receptor[/caption] This is an opinion post Background I'd never heard of Serotonin until I was diagnosed with Neuroendocrine Cancer in 2010. It is frequently discussed, often with contrasting views from the respondents. One common assumption/question is that it is responsible for many things that can go wrong with Neuroendocrine Cancer patients who have serotonin-producing tumours. To a certain extent, that's true but statement such as "it's the hormones" is an easy assumption to make; or an easy answer to give in response to a complex set of circumstances. It's difficult to get a definitive answer and the science…

Read More

We Remember – A message of hope in the time of the Coronavirus!

I really like this video because it covers the positives of the coronavirus crisis, despite the daily gloom. At the time of writing, it’s clear things will get worse before they improve. However, this crisis will end sometime, hopefully soon; and we’ll look back on this period with multiple emotions. Of course we will be […]

My Self Isolation Diary – COVID-19

COVID-19 reminds me of some of the issues with Neuroendocrine Cancer e.g. is this a normal day to day cold/flu/chest issue or is it COVID-19? At least COVID-19 is the number one awareness topic in the universe so people are very very aware. Just as well because it has the potential to kill hundreds of […]

COVID-19 and Cancer Treatment and Surveillance

NEW CONTENT added 2 April 2020: See below for UK NET Specialist video and text regarding all issues with treatment and surveillance OPINION. My third article on the COVID-19 issue and based on the top topic currently in my private group – treatment and surveillance concerns over the period of COVID-19 restrictions. I have no […]

Why Coronavirus Anxiety is Hard to Control – a Neuroendocrine Cancer patient perspective

OPINION. I guess many people are feeling pretty scared right now. Add age, a chronic disease, cancer, a lung illness or any condition that has a level of immunosuppression, and it seems to become even more scarier when you read the news. I think the ‘not knowing’ how this crisis is going to pan out […]

Coronavirus 19 (COVID-19): risks for cancer patients

This is not medical advice UPDATED 5 Apr 2020 – excellent video meeting between Elyse from NET Research Foundation and Dr Mark Lewis. Dr Lewis is an Oncologist and also a NET patient so he speaks with both aspects in mind. See article 6 below. UPDATED 28 Mar 2020– see two links from Neuroendocrine Cancer […]

Neuroendocrine Cancer Nutrition Series Part 6 – featuring the 2020 video series by Tara Whyand RD

Nutrition is an important subject for many cancers but it is particularly important for Neuroendocrine Cancer. In the previous parts of this series I focused on the following: Article 1 – Vitamin and Mineral Challenges. This was co-authored by Tara Whyand, UK’s most experienced NET Specialist Dietitian. This blog provides a list of vitamins and minerals which […]

Clinical Trial: Lu-177 DOTATOC (PRRT) in adult subjects with Somatostatin receptor (SSTR) positive Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymic Neuroendocrine Tumors

Excellent news for those who don’t have Gastroenteropancreatic NETs (GEP-NETs). A trial of PRRT is being set-up for the less common types of NET incuding those with an unknown primary. Using the DOTATOC radionuclide rather then the Lutathera model of using DOTATATE, this trial will cater for Pulmonary, Pheochromoctyoma, Paraganlioma, Unknown Primary and Thymic Neuroendocrine […]

Oral Octreotide using RaniPill™

Rani Therapeutics, a leader in oral biologics, has announced positive results from the Phase I clinical study of its orally-delivered version of octreotide, Octreotide-RP, a drug used in the treatment of acromegaly and neuroendocrine tumors. The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the […]